Diabetic Macular Edema

Factors including a longer diabetes duration and lower eGFR were associated with suboptimal treatment response to aflibercept in patients with DME.

Faricimab shows improved visual and anatomic outcomes in eyes with nAMD previously treated with aflibercept or brolucizumab.

New phase 2 study findings link levosulpiride treatment for 8 weeks with improved visual and structural outcomes and no significant adverse side effects.

The analysis found any metformin use decreased the odds of developing dry AMD, particularly cumulative 2-year doses of 1 to 270 g and 271 to 600 g.

Findings from two recent studies provide insight into the association between anti-VEGF treatment for retinal diseases and the risk of kidney injury.

Results from a secondary analysis of PALADIN showed the 0.19-mg implant was associated with mostly stable IOPs in eyes with DME over a 36-month period.

Results from the 2-year retrospective cohort study showed patients with DME and extremely high or low eGFR had a greater decline in eGFR.

A treat-and-extend faricimab regimen may improve functional and anatomical outcomes at 1 year in patients with DME recalcitrant to aflibercept treatment.

With approval, aflibercept 8 mg becomes the first and only treatment approved in wet AMD and DME for immediate dosing at 8-week and up to 16-week intervals following 3 initial monthly doses.

Initial real-world experience with ranibizumab biosimilar agents revealed no unexpected adverse outcomes across 16 retina centers, with similar efficacy to reference ranibizumab.

Results from the CT-P42 3.1 Study indicate the therapeutic equivalence of the aflibercept biosimilar, CT-P42, to the reference product in eyes with DME.

Real-world data show the benefits of DEX implants prior to cataract surgery to achieve sufficient postoperative inflammation management and limit deterioration.

Each month, our editorial staff compiles a recap of the top news in ophthalmology from the past month. Our July 2023 month-in-review features a recap of conference coverage from the ASRS 41st Annual Scientific Meeting.

Results from the real-world AUSSIEDEX study suggest dexamethasone implant significantly improved anatomic outcomes at 52 weeks and showed no new safety concerns.

Large learning model-based platforms provide largely inaccurate responses to questions concerning vitreoretinal disease and remain inconsistent on repeat queries.

New 96-week data from PULSAR show patients treated with aflibercept 8 mg achieved good durability and maintained visual acuity gains from year 1 through year 2 of study.

Anatomic and visual improvements with high-dose aflibercept in CANDELA indicate a potential therapeutic benefit over aflibercept 2 mg, despite not achieving statistical significance.

Results from FARETINA-DME indicate a majority of eyes with DME began extending treatment intervals after 1-2 initial doses of faricimab.

Positive topline results from the phase 3 trial suggest once-daily OCS-01 met both primary trial endpoints for the treatment of inflammation and pain following cataract surgery.

Data from PK profiles and safety analyses of intravitreal sozinibercept suggest the promise of the drug in combination with standard anti-VEGF agents for AMD and DME.

Presented at ASRS 2023, results from a posthoc analysis of YOSEMITE/RHINE suggest a potential anti-fibrotic effect of faricimab versus aflibercept in eyes with DME.

Experts discuss the recent DRCR Protocol AC study comparing aflibercept monotherapy vs bevacizumab first therapy for patients with diabetic macular edema (DME).

Experts discuss the results of Protocol T study comparing anti-vascular endothelial growth factor (Anti-VEGF) agents for the treatment of diabetic macular edema (DME).

Presented at ASRS 2023, results suggest the potential proof-of-concept for the safety, tolerability, and efficacy of UBX1325 in patients with DME.

Late-breaking findings at ASRS 2023 suggest daily home OCT imaging is sufficient for remotely monitoring fluid among patients with treatment-naïve nAMD.

Presented at ASRS 2023, the results showed clinically meaningful reductions in anti-VEGF treatment burden at all dose levels of intravitreal 4D-150 in patients with a high anti-VEGF need.

However, the meta-analysis of patients treated with ranibizumab suggests a similar proportion of patients achieved DME resolution, regardless of baseline DR severity, by month 24.

Experts discusses the unique challenges managing the care of patients with diabetic macular edema (DME).

Experts discuss prospective therapies and improved outcome targets for patients with neovascular age-related macular degeneration (nAMD).